Megan S. Schuler

May 20, 2024 | rand.org | Megan S. Schuler |Andrew W. Dick |Adam Gordon |Brendan Saloner

BackgroundWe examined the number and characteristics of high-volume buprenorphine prescribers and the nature of their buprenorphine prescribing from 2009 to 2018. MethodsIn this observational cohort study, IQVIA Real World retail pharmacy claims data were used to characterize trends in high-volume buprenorphine prescribers (clinicians with a mean of 30 or more active patients in every month that they were an active prescriber) during 2009–2018.

Jul 14, 2023 | rand.org | Megan S. Schuler |Brendan Saloner |Adam Gordon |Andrew W. Dick

Background Buprenorphine is a key medication to treat opioid use disorder (OUD). Since its approval in 2002, buprenorphine access has grown markedly, spurred by major federal and state policy changes. This study characterizes buprenorphine treatment episodes during 2007 to 2018 with respect to payer, provider specialty, and patient demographics.